AGENDA para profesionales

04 julio 2019
05 julio 2019

International preceptorship center of excellence in women's cancer

Current therapy and emerging approaches

4th JULY, 2019

09.00-9.15 Welcome and introductory remarks
Dr Antonio González-Martín

Introduction to the multidisciplinary approach in advanced ovarian cancer

9.15-11.00 Advanced ovarian cancer: Primary debulking surgery (PDS)
Dr. Luis Chiva

  • Primary cytoreductive surgery. Goals and limits.
  • Presentation of the necessary procedures to achieve optimal cytoreduction.
  • Selection of patients for PDS vs neoadjuvant chemotherapy.
  • Chemotherapy as the first choice: the role of Interval Surgery; pros and cons of neoadjuvant chemotherapy.
  • Critical appraisal of HIPEC.
  • Discussion.

11:00-11:30 Coffee break

11:30-13:30 Ovarian cancer: front-line medical approach mutations
Dr. Antonio González-Martín

  • Histopathology and new concepts in molecular biology of ovarian cancer (Dr. Espinosa).
  • BRCA and ovarian cancer. Prognostic and predictive implications.
  • Standard front-line therapy (including intraperitoneal therapy, dose-dense paclitaxel and antiangiogenic agents).
  • Update of the ESMO-ESGO Guideline.
  • Discussion.


13:30-15:00 Lunch

15:00-16:00

  • Genetic Counselling: Breast and ovarian hereditary syndromes. The CUN perspective
    Dra. Luisa Sánchez
  • PARP inhibitors in ovarian cancer: from mechanism of action to new clinical trials design
    Dr Antonio González-Martín

16:00-17:30 Tumour board

  • Case series focusing on patients with primary and recurrent disease.
    Dra Luisa Sánchez, Dr Iñigo Espinosa, Dr Luis Chiva, Dr Antonio González-Martín

17:30 End of the session day 1


5th JULY, 2019

09.00-11.30 Optimal management of recurrent disease: how to deal with the universe of differentuseful drugs
Dr Antonio González-Martín and Dr. Luis Chiva

  • Defining recurrence.
  • When to start treatment in case of relapse?
  • Selecting patients for successful surgical salvage therapy.
  • Update of ESMO-ESGO Guidelines:
  • Recurrent disease and platinum seems to be an option.
  • Recurrent disease and platinum seems not to be an option.
  • Immunotherapy in ovarian cancer.
  • Discussion.

11:30-12:00 Coffee break

12:00-13:30 UPDATE in TRIPLE NEGATIVE AND BRCAm BREAST CANCER

  • Introduction to multidisciplinary approach and surgical aspects of TNBC
    Dra. Isabel Rubio
  • Update in TNBC from the medical oncology perspective
    Dra. Luisa Sánchez

13:30-15:00 Lunch

15:00-16:00

  • Current implication of BRCA in breast cancer
    Dra. Isabel Rubio
  • PARP inhibitors in breast cancer: where do we stand and where are we heading?
    Dra. Natalia Ramírez Merino

16:00-17:00 Tumour board Case series focusing on patients with primary and recurrent disease.
Dra. Luisa Sánchez / Dra. Isabel Rubio / Natalia
Ramírez Merino / Dr. Antonio González

17:00-17:30 Final remarks and end of the course

SEDE
Clínica Universidad de Navarra. Sede Madrid
Calle Marquesado de Sta. Marta 1
28027 Madrid

T +34 91 353 19 20

tal vezLE INTERESE

POR QUÉ VENIR A
LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra

ESTANCIAS
FORMATIVAS

La Clínica ofrece la posibilidad de realizar estancias en los departamentos para así completar la formación.

Imagen de profesionales trabajando en la Clínica Universidad de Navarra

ACTIVIDAD
INVESTIGADORA

Nuestros profesionales siguen investigando y tienen a su disposición todas las instalaciones y recursos de la Universidad de Navarra.

Imagen de un investigador del Área de Terapia Celular de la Clínica Universidad de Navarra